Fulvestrant Information & Fulvestrant Links at HealthHaven.com

Fulvestrant
Systematic (IUPAC) name
	13-methyl-7-[9-( 4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]- 7,8,9,11,12,13,14,15,16, 17-decahydro- 6H-cyclopenta[a] phenanthrene-3,17-diol
Identifiers
CAS number	129453-61-8
ATC code	L02BA03
PubChem	104741
DrugBank	APRD00654
Chemical data
Formula	C32H47F5O3S
Mol. mass	606.772 g/mol
Pharmacokinetic data
Bioavailability	?
Protein binding	99%
Metabolism	?
Half life	40 days
Excretion	?
Therapeutic considerations
Pregnancy cat.	D
Legal status	Rx only
Routes	Intramuscular injection
	(what is this?) (verify);

Fulvestrant, also known as ICI 182,780, is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.^[1] It is administered as a once-monthly injection.

Fulvestrant is marketed by AstraZeneca with the brand name Faslodex.

[edit] Clinical uses

Fulvestrant is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy.

[edit] External links

[edit] References

^ S. Kansra, S. Yamagata, L. Sneade, L. Foster & N. Ben-Jonathan, 2005. "Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release." Mol Cell Endocrinol. 2005 Jul 15;239(1-2):27-36.

[0] S. Kansra, S. Yamagata, L. Sneade, L. Foster & N. Ben-Jonathan, 2005. "Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release." Mol Cell Endocrinol. 2005 Jul 15;239(1-2):27-36.

[1]